Prevalence of Secondary Cardiac Damage in Rheumatic Fever Patients and Penicillin Secondary Prophylaxis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03183180|
Recruitment Status : Not yet recruiting
First Posted : June 9, 2017
Last Update Posted : June 9, 2017
According to American Heart Association criteria, patients who have had Rheumatic Fever (RF) should be treated with antibiotic prophylaxis. Continuous prophylaxis is recommended in patients with well-documented histories of RF and in those with evidence of rheumatic heart disease.
There is a limited data regarding adherence of patients to treatment and efficacy of treatment.
In this study, patients with RF who are older than 21 years will be collected from a computerized database of 'Maccabi Healthcare Services', one of the biggest Israeli Health Funds. Patients will be assigned to the study after obtaining informed consent.
Previous adherence to antibiotic prophylaxis will be examined according to computerized database of drugs which were issued to the patient since RF diagnosis.
Past history of cardiac involvement, including past Echocardiograms, will be collected from computerized database. In addition, the current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination.
|Condition or disease||Intervention/treatment|
|Secondary Cardiac Damage in Rheumatic Fever||Diagnostic Test: Echocardiogram|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prevalence of Secondary Cardiac Damage in Rheumatic Fever Patients and Adherence to Penicillin Secondary Prophylaxis|
|Anticipated Study Start Date :||June 2017|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||May 2019|
Diagnostic Test: Echocardiogram
- Cardiac function including vulvar involvement [ Time Frame: 60 days ]Cardiac morphology and function measured by echocardiography